Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Free Report) CFO Michael Celano bought 18,460 shares of the business’s stock in a transaction on Wednesday, November 11th. The stock was purchased at an average price of $2.71 per share, with a total value of $50,026.60. Following the completion of the transaction, the chief financial officer directly owned 234,245 shares of the company’s stock, valued at $634,803.95. This trade represents a 8.55% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.
Larimar Therapeutics Stock Up 11.9%
NASDAQ LRMR traded up $0.32 on Friday, reaching $3.02. 2,531,459 shares of the stock traded hands, compared to its average volume of 1,257,255. Larimar Therapeutics, Inc. has a 12 month low of $1.91 and a 12 month high of $6.42. The company has a market cap of $313.72 million, a price-to-earnings ratio of -1.55 and a beta of 0.73. The firm’s fifty day simple moving average is $2.93 and its 200 day simple moving average is $3.76.
Trending Headlines about Larimar Therapeutics
Investors following LRMR have been watching these headlines:
- Positive Sentiment: CEO Carole Ben-Maimon, CFO Michael Celano, COO John B. Jr. Harlow, insider Gopi Shankar, and directors Frank Thomas and Joseph Truitt together purchased 52,810 shares for roughly $195,000. Director Thomas Hamilton separately bought 70,000 shares for $186,900. Insider purchase report Hamilton SEC filing
- Neutral Sentiment: The supplied coverage also notes H.C. Wainwright maintained a Buy rating; no rating change or fresh price-moving catalyst was reported. Analyst rating report
Institutional Inflows and Outflows
Analysts Set New Price Targets
A number of research analysts recently issued reports on the company. Wall Street Zen lowered Larimar Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday. Wedbush reissued an “outperform” rating on shares of Larimar Therapeutics in a report on Tuesday, November 10th. Leerink Partners assumed coverage on shares of Larimar Therapeutics in a research report on Monday, September 14th. They set an “outperform” rating and a $13.00 price objective for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Larimar Therapeutics in a research report on Thursday, October 15th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Larimar Therapeutics presently has a consensus rating of “Buy” and an average target price of $10.33.
Get Our Latest Stock Report on LRMR
About Larimar Therapeutics
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, focused on developing treatments for rare diseases. Its lead drug candidate is nomlabofusp, formerly known as CTI-1601, an engineered fusion protein designed to deliver frataxin to mitochondria. Nomlabofusp is being developed to treat Friedreich’s ataxia, a rare, inherited neurodegenerative disorder associated with insufficient frataxin. Larimar’s approach uses a cell-penetrating peptide to transport frataxin into cells and mitochondria, with the goal of addressing an underlying cause of the disease rather than only treating its symptoms.
Recommended Stories
- Five stocks we like better than Larimar Therapeutics
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
